跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 12,623 条关于
“CD64 receptor”
全部
12,623
临床试验
6,212
药物
1,440
机构
30
资讯
4,941
2年前
TREMFYA® (guselkumab) Approved by FDA for Ulcerative Colitis Treatment
去年
TREMFYA Becomes First IL-23 Inhibitor to Reduce Structural Damage in Psoriatic Arthritis
2个月前
Immune Cells Use Previously Unknown TCR-Dependent, MHC-Independent Pathway to Eliminate AML
9个月前
OncoPrecision's First-in-Class CD64-Targeting ADC ONC001 Selected for Oral Presentation at ASH 2025
去年
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya in Ulcerative Colitis
去年
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya in Ulcerative Colitis
去年
J&J Seeks FDA Approval for Subcutaneous Guselkumab Induction in Ulcerative Colitis
去年
Johnson & Johnson Seeks FDA Approval for Subcutaneous TREMFYA® in Ulcerative Colitis
2年前
Tremfya (Guselkumab) Approved by FDA for Ulcerative Colitis Treatment
去年
Guselkumab Approved for Ulcerative Colitis, Tradipitant Receives CRL: GI News from September 2024
第 1 页,共 495 页
上一页
下一页